Select Biosciences Ltd, Feb 2009, Pages: 310
for apoptosis modulators in cancer, CNS diseases, and chronic inflammation/autoimmunity.
- Gain up-to-date competitive intelligence on apoptosis-modulating pipelines and identify the most promising drugs under
Avance, March 2009, Pages: 38
The report "Success Rates in Biotech - Going The Wrong Way" summarises our review of 211 public biotech companies comprising over 1,500 drug development projects. We have studied the clinical
La Merie, Nov 2010, Pages: 22
Antagonist R&D Pipelines 1. IL-1/R Antagonist
- IL-1 and IL-1R Antagonists in autoimmune & Inflammation
- IL-1 and IL-1R Antagonists in Metabolism
- IL-1 and IL-1R Antagonists in Pulmonary & Respiratory
Jain PharmaBiotech, Feb 2012, Pages: 276
This report describes the latest concepts of the role of nitric oxide (NO) in health and disease as a basis for therapeutics and development of new drugs. Major segments of the market for nitric
Business Insights, Jan 2010, Pages: 106
of these products must be approached carefully. This report uses a mixture of case studies and data from secondary sources to elucidate the key issues in the development of orphan drugs and ways to navigate them
Biophoenix Limited, Feb 2009, Pages: 312
modulators in cancer, CNS diseases, and chronic inflammation/autoimmunity. - Gain up-to-date competitive intelligence on apoptosis-modulating pipelines and identify the most promising drugs under development
Business Insights, May 2009, Pages: 335
companies. This report identifies areas of innovation and opportunity for kinase targeting drugs in cancer and examines the non-cancer applications of kinase drugs across inflammatory and autoimmune diseases
GBI Research, Dec 2010, Pages: 198
such as cancer, inflammation, diabetes and rheumatoid arthritis, as well as major biosimilars in the drug classes erythropoietin, insulin analogs and human growth hormones The report also gives insights
Jain PharmaBiotech, Feb 2012, Pages: 864
This report follows the broad definition of a biomarker as a characteristic that can be objectively measured and evaluated as an indicator of normal biological or pathogenic processes as well
La Merie, Jan 2009, Pages: 21
processes including inflammation and autoimmunity.
The report includes a compilation of current active projects in research and development of subtype-selective and multi-PKC inhibitors as well as of PKC
Global Markets Direct, Nov 2011, Pages: 48
SEEK – Product Pipeline Review – H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “Seek - Product Pipeline Review - H2 2011” provides data on the Seek’s research and development
GlobalData, Dec 2011, Pages: 79
Crohn’s Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Crohn’s Disease (CD
Datamonitor, July 2010, Pages: 245
assessing induction and maintenance treatment in separate studies of new drugs will play a significant role in drug labeling, particularly for the European Medicines Agency.
Two key late-stage pipelinedrugs
La Merie, Nov 2010, Pages: 26
molecules. In addition, the report lists company-specific S1P R&D pipelines. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action
Global Markets Direct, Nov 2011, Pages: 44
Description
Mechanism of Action
R&D Progress
Ilaris - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Inflammation And Autoimmune Diseases - Drug Profile
Fuji-Keizai USA, Inc., April 2003, Pages: 162
of companies and their products among the therapeutic classes of emerging biopharmaceutical companies.
AUTOIMMUNE/INFLAMMATION MARKET SEGMENT
- Figure 3. Distribution of lead drug candidates by stage
GlobalData, Oct 2011, Pages: 131
Rheumatoid Arthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Rheumatoid Arthritis
La Merie, Jan 2009, Pages: 37
active projects in research and development of anti-CD20 antibodies. In addition, the report lists company-specific R&D pipelines of anti-CD20 antibodies. Competitor projects are listed in a tabular format
GlobalData, Oct 2011, Pages: 14
Cytokine PharmaSciences, Inc. - Product Pipeline Analysis Summary Cytokine PharmaSciences, Inc. (CPSI) is engaged in the development and manufacture of drug delivery products. The company's focus
